Sahil Pharma Chemicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-07-2024
- Paid Up Capital ₹ 1.00 M
as on 04-07-2024
- Company Age 26 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 20.02%
(FY 2022)
- Profit 134.75%
(FY 2022)
- Ebitda 116.00%
(FY 2022)
- Net Worth 28.95%
(FY 2022)
- Total Assets -7.86%
(FY 2022)
About Sahil Pharma Chemicals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Vivek Tyagi and Mala Tyagi serve as directors at the Company.
- CIN/LLPIN
U24230MH1998PTC116734
- Company No.
116734
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sahil Pharma Chemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Tyagi  | Director | 30-Sep-1998 | Current |
| Mala Tyagi | Director | 18-Mar-2019 | Current |
Financial Performance of Sahil Pharma Chemicals.
Sahil Pharma Chemicals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.02% increase. The company also saw a substantial improvement in profitability, with a 134.75% increase in profit. The company's net worth Soared by an impressive increase of 28.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sahil Pharma Chemicals?
In 2022, Sahil Pharma Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ind-Expo Oleochemicals Private LimitedActive 33 years 30 daysVivek Tyagi and Mala Tyagi are mutual person
- Goodluck Metals Private LimitedActive 18 years 6 months
Vivek Tyagi and Mala Tyagi are mutual person
- Malade Chemicals Private LimitedActive 34 years 9 months
Vivek Tyagi and Mala Tyagi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sahil Pharma Chemicals?
Sahil Pharma Chemicals has a workforce of 12 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sahil Pharma Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sahil Pharma Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
